Tag: appointment

SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance’s pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer.

CAMBRIDGE, United Kingdom and MONTREAL, July 10, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and the expansion of its research team. These developments represent a significant milestone in the company’s ongoing progress in advancing its RNA-based immunotherapies, known as CryptiVax™, into clinical trials.

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the XPLR Infrastructure class action lawsuit seeks to represent purchasers or acquirers of XPLR Infrastructure, LP f/k/a NextEra Energy Partners, LP (NYSE: XIFR) securities between September 27, 2023 and January 27, 2025, inclusive (the “Class Period”). Captioned Alvrus v. XPLR Infrastructure, LP f/k/a NextEra Energy Partners, LP, No. 25-cv-01755 (S.D. Cal.), the XPLR Infrastructure class action lawsuit charges XPLR Infrastructure, NextEra Energy, Inc., and certain of XPLR Infrastructure’s top former executives with violations of the Securities Exchange Act of 1934.

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.

VANCOUVER, CANADA, July 09, 2025 (GLOBE NEWSWIRE) -- QUEST WATER GLOBAL, INC. (OTCID: QWTR) ("Quest" and/or the "Company"), is pleased to announce the appointment of Isaac Mutambayi Kalonji Jr. III as the Company’s Chief Operating Officer (“COO”) and Executive Director.

Ekopak (EKOP:xbru), a company specialized in circular water solutions, announces the appointment of Jean-Baptiste De Cuyper as its new CEO. This appointment follows the earlier communication of May 12, 2025, in which the company announced its intention to appoint an external candidate for this key role. The appointment is part of Ekopak's broader efforts to strengthen its governance and management structure.